Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 26 04 2024
accepted: 09 08 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 13 9 2024
Statut: epublish

Résumé

Pre-existent pools of coronavirus-specific or cross-reactive T cells were shown to shape the development of cellular and humoral immune responses after primary mRNA vaccination against SARS-CoV-2. However, the cellular determinants of responses to booster vaccination remain incompletely understood. Therefore, we phenotypically and functionally characterized spike antigen-specific T helper (Th) cells in healthy, immunocompetent individuals and correlated the results with cellular and humoral immune responses to BNT162b2 booster vaccination over a six-month period. Blood of 30 healthy healthcare workers was collected before, 1, 3, and 6 months after their 3rd BNT162b2 vaccination. Whole blood was stimulated with spike peptides and analyzed using flow cytometry, a 13-plex cytokine assay, and nCounter-based transcriptomics. Spike-specific IgG levels at 1 month after booster vaccination correlated with pre-existing CD154+CD69+IFN-γ+CD4+ effector memory cells as well as spike-induced IL-2 and IL-17A secretion. Early post-booster (1-month) spike IgG levels (r=0.49), spike-induced IL‑2 (r=0.58), and spike-induced IFN‑γ release (r=0.43) correlated moderately with their respective long-term (6-month) responses. Sustained robust IgG responses were significantly associated with S-specific (CD69+±CD154+±IFN-γ+) Th-cell frequencies before booster vaccination (p=0.038), especially double/triple-positive type-1 Th cells. Furthermore, spike IgG levels, spike-induced IL‑2 release, and spike-induced IFN‑γ release after 6 months were significantly associated with increased IL‑2 & IL‑4, IP‑10 & MCP1, and IFN‑γ & IP‑10 levels at 1 month post-booster, respectively. On the transcriptional level, induction of pathways associated with both T-cell proliferation and antigen presentation was indicative of sustained spike-induced cytokine release and spike-specific IgG production 6 months post-booster. Using support vector machine models, pre-booster spike-specific T-cell frequencies and early post-booster cytokine responses predicted sustained (6-month) responses with F1 scores of 0.80-1.00. In summary, spike-specific Th cells and T-cellular cytokine signatures present before BNT162b2 booster vaccination shape sustained adaptive cellular and humoral responses post-booster. Functional T-cell assays might facilitate early identification of potential non-responders.

Identifiants

pubmed: 39267758
doi: 10.3389/fimmu.2024.1423766
pmc: PMC11390417
doi:

Substances chimiques

Cytokines 0
BNT162 Vaccine 0
Spike Glycoprotein, Coronavirus 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Immunoglobulin G 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1423766

Informations de copyright

Copyright © 2024 Page, Dennehy, Mueller, Girl, Loell, Buijze, Classen, Messmann, Roemmele, Hoffmann, Wurster and Fuchs.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Immunol. 2011 Jul 10;12(8):786-95
pubmed: 21743478
Immunity. 2022 Oct 11;55(10):1924-1939.e5
pubmed: 35985324
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Vaccines (Basel). 2022 Aug 25;10(9):
pubmed: 36146474
Med Mycol. 2017 Feb 1;55(2):223-227
pubmed: 27486216
Int J Mol Sci. 2023 Jul 20;24(14):
pubmed: 37511464
Nat Rev Immunol. 2022 Jan;22(1):57-65
pubmed: 34876702
Trop Med Infect Dis. 2022 May 22;7(5):
pubmed: 35622708
Vaccines (Basel). 2022 Dec 13;10(12):
pubmed: 36560542
J Immunol Methods. 2016 Jul;434:73-82
pubmed: 27129808
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
JCI Insight. 2022 Apr 8;7(7):
pubmed: 35230977
Nat Commun. 2023 Jun 10;14(1):3440
pubmed: 37301910
Rev Med Virol. 2024 Jan;34(1):e2515
pubmed: 38282403
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Adv Lab Med. 2021 Dec 20;3(1):39-50
pubmed: 37359438
J Exp Med. 2018 Nov 5;215(11):2705-2714
pubmed: 30232200
Br J Haematol. 2022 Jun;197(6):709-713
pubmed: 35262920
J Pers Med. 2022 Oct 17;12(10):
pubmed: 36294868
Eur J Immunol. 2021 Jul;51(7):1732-1747
pubmed: 33844287
Sci Immunol. 2017 Aug 25;2(14):
pubmed: 28842433
Int J Lab Hematol. 2013 Jun;35(3):344-50
pubmed: 23590661
Nat Commun. 2022 Jan 10;13(1):80
pubmed: 35013199
Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130
pubmed: 32853163
Med Mycol. 2020 Feb 1;58(2):187-196
pubmed: 31095327
J Fungi (Basel). 2021 Jun 08;7(6):
pubmed: 34201183
Front Immunol. 2022 Jul 26;13:944713
pubmed: 35990661
Open Forum Infect Dis. 2020 Nov 08;8(1):ofaa547
pubmed: 33447629
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
Front Immunol. 2022 Aug 05;13:926318
pubmed: 35990701
J Infect. 2022 Nov;85(5):545-556
pubmed: 36089104
Immunity. 2019 May 21;50(5):1172-1187.e7
pubmed: 31076359
Immunology. 2000 Jul;100(3):269-80
pubmed: 10929048
J Immunol. 2008 Sep 1;181(5):3665-73
pubmed: 18714042
Clin Exp Vaccine Res. 2022 Jan;11(1):96-103
pubmed: 35223670
J Leukoc Biol. 2022 Feb;111(2):355-365
pubmed: 34730247
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
J Clin Invest. 2021 May 17;131(10):
pubmed: 33830946
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
J Investig Med. 2022 Aug;70(6):1429-1432
pubmed: 35768140
Mycoses. 2018 Aug;61(8):549-560
pubmed: 29611226
Int Immunopharmacol. 2023 Apr;117:109968
pubmed: 37012880

Auteurs

Lukas Page (L)

Institute for Laboratory Medicine and Microbiology, University Hospital of Augsburg, Augsburg, Germany.

Kevin Dennehy (K)

Institute for Laboratory Medicine and Microbiology, University Hospital of Augsburg, Augsburg, Germany.

Katharina Mueller (K)

Bundeswehr Institute of Microbiology, Munich, Germany.

Philipp Girl (P)

Bundeswehr Institute of Microbiology, Munich, Germany.
Central Institute of the Bundeswehr Medical Service, Munich, Germany.
Institute for Infectious Diseases and Zoonoses, Department of Veterinary Sciences, Faculty of Veterinary Medicine, Ludwig Maximilians University Munich, Munich, Germany.

Eva Loell (E)

Institute for Laboratory Medicine and Microbiology, University Hospital of Augsburg, Augsburg, Germany.

Hellen Buijze (H)

Institute for Laboratory Medicine and Microbiology, University Hospital of Augsburg, Augsburg, Germany.

Johanna-Maria Classen (JM)

Internal Medicine III - Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg, Germany.

Helmut Messmann (H)

Internal Medicine III - Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg, Germany.

Christoph Roemmele (C)

Internal Medicine III - Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg, Germany.

Reinhard Hoffmann (R)

Institute for Laboratory Medicine and Microbiology, University Hospital of Augsburg, Augsburg, Germany.

Sebastian Wurster (S)

Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Andre Fuchs (A)

Internal Medicine III - Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH